Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 August 2021 | Story Lacea Loader | Photo Supplied
Dr Millard Arnold, UFS Council Member and Senior Consultant at Bowman Gilfillan.

Dr Millard Arnold, Council Member of the University of the Free State (UFS) and Senior Consultant at Bowman Gilfillan, recently contributed to a noteworthy book on leadership and a book on responsive universities. His experience as a journalist and later as a seasoned leader and keynote speaker positioned him well to participate in the book: The Book Every Upcoming, New, and Seasoned Leader Needs to Read – Lessons From Leading Business Minds and Thought Leaders. 

From surviving to thriving

Incorporating collective leadership wisdom for both the leaders of tomorrow and the leaders of today, the book is full of lessons, insights, pep talks, advice, and direction for building your own style and approach to great leadership, and not to shy away from the ecstasy (and sometimes agony) of becoming a significant leader. Packed with the contributions of 48 authors, the book is the antidote to the lack of mentorship in the field. Authors include Brand Pretorius, Edwin Cameron, Marnus Broodryk, Nyimpini Mabunda, and Roze Phillips – to name a few. 

Giving problems to solutions

Dr Arnold’s contribution focuses on fishing out the valuable leadership principles from the sea of leaderships that we are drowning in. “I have found myself in positions of leadership and have had to develop a number of thoughts on leadership which have helped guide me in determining how best to lead,” he writes. This guided him to discover the true essence of leadership, which is problem solving. He asserts that “if there are no difficulties to overcome, no problems to resolve, the leadership is unnecessary”. Leadership has its genesis in problems, he believes. 

Effective leaders make things happen

Among the profound insights that Dr Arnold shares, he highlights the notion that great leaders must understand the problem and have the vision to see the solution. Inevitably, this necessitates the leader to take some risks and to persuade others to get on board. This is only possible if the leader has integrity and ultimately deliver on the promise made. He advises leaders to “ask good questions, listen to the answers, assess the reality, be empathic, and spend a great deal of time on self-reflection”.

Universities must remain relevant 

Dr Arnold also contributed a chapter titled, Poverty, Inequity and Decolonisation: Are Business Schools Responsive to the Challenge? in a book by Chris Brink, The Responsive University and the Crisis in South Africa. The book brings together contributions on the issue of responsiveness from several international university leaders. Dr Arnold’s chapter presents an overview of the impact of colonialism and capitalism on the African mind set and stresses how different South African business schools have responded to the task of being responsive to the challenges confronting the country. It argues that, if carefully managed, business schools can, and should be, vehicles to promote and facilitate positive and constructive change.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept